Novartis Cosentyx® (secukinumab) receives positive CHMP

Positive opinion could expand the role of Cosentyx®(secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic...

Related Keywords

Hamburg ,Germany ,Brazil ,Japan ,United States ,America ,Isabella Zinck ,Michael Meo ,Thomas Hungerbuehler ,Dermatol Venereol ,Rachel Fink Thoma ,Samir Shah ,Parag Mahanti ,Julie Masow ,Todd Fox ,Sloan Simpson ,Ivan Foeldvari ,Alina Levchuk ,Twitter ,Ministry Of Health ,American College Of Rheumatology ,Novartis ,Novartis Europharm ,Virtual Congress ,Committee For Medicinal Products Human Use ,Rheumatology Research Alliance Registry ,Hamburg Centre For Pediatric Rheumatology ,Novartis Us External Communications ,European Alliance Of Associations ,International League ,Exchange Commission ,Novartis Pharma Communications ,European Medicines Agency ,Novartis Pharmaceuticals Corp ,Medicinal Products ,Human Use ,Hamburg Centre ,Pediatric Rheumatology ,Global Head ,Medical Affairs Immunology ,Provides Sustained Improvements ,Psoriatic Arthritis ,Pooled Safety ,Enthesitis Related Arthritis ,Juvenile Psoriatic Arthritis ,Primary Results ,Treatment Withdrawal ,European Alliance ,Associations For Rheumatology ,Treatment In Children And Adolescents ,Efficacy And Safety Results From ,American College ,Juvenile Arthritis ,Childhood Arthritis ,Rheumatology Research Alliance ,Term Outcomes ,Juvenile Idiopathic Arthritis ,Eighteen Years ,Arthritis Care Res ,East Hanover ,Extended Use ,Swiss Stock Exchange Novn ,Novartis Pharma Ag ,Reimagine Medicine ,Media Release ,Innovation ,